93
Participants
Start Date
August 15, 2022
Primary Completion Date
May 1, 2024
Study Completion Date
November 30, 2025
RO7247669
Participants will receive intravenous (IV) RO7247669 Q3W
Auckland City Hospital, Cancer and Blood Research, Auckland
Melanoma Institute Australia, North Sydney
Coffs Harbour Health Campus, Coffs Harbour
Princess Alexandra Hospital, Woolloongabba
Wellington Hospital, Wellington
One Clinical Research, Nedlands
Medipol Mega Üniversite Hastanesi Göztepe, Istanbul
Hospital de Clínicas de Porto Alegre X, Porto Alegre
Hospital de Cancer de Barretos, Barretos
Instituto do Cancer do Estado de Sao Paulo - ICESP, São Paulo
Hospital Sírio-Libanês, São Paulo
Princess Margaret Cancer Centre, Toronto
Všeobecná fakultní nemocnice v Praze, Prague
District General Hospital of Athens Laiko, Athens
Uniwersyteckie Centrum Kliniczne, Gda?sk
Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie, Warsaw
Narodny Onkologicky Ustav, Bratislava
POKO Poprad, Poprad
Hospital Universitari Vall d'Hebron, Barcelona
Hospital Clínic i Provincial, Barcelona
Adana Baskent University Hospital, Adana
Memorial Ankara Hastanesi, Ankara
Hoffmann-La Roche
INDUSTRY